SCHEMBL3016263

SCHEMBL3016263

Cc1cc(C)c(-c2csc(N3CCN(S(=O)(=O)c4cccc(Cl)c4Cl)CC3)n2)c(C)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.48
KMT2A Q03164 3/20 0.48
MAPT P10636 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 2/20 0.48
MAPK1 P28482 2/20 0.45
TSHR P16473 1/20 0.44
USP2 O75604 1/20 0.44
RECQL P46063 1/20 0.44
HSD17B10 Q99714 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
TP53 P04637 1/20 0.42
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
CHRM1 P11229 1/20 0.39
AR P10275 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008564 0.93 KMT2A (0.51) LMNAKMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL3009220 0.92 KMT2A (0.50) LMNAKMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL3016895 0.89 LMNA (0.54) LMNAKMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL3008907 0.86 AR (0.56) LMNAKMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL3011207 0.86 MAPT (0.53) LMNAKMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL3011439 0.86 LMNA (0.60) LMNAKMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL3011983 0.85 KMT2A (0.54) LMNAKMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL3012120 0.85 CTSS (0.43) LMNAKMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL3020238 0.85 MAPT (0.55) LMNAKMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL3018738 0.85 ALDH1A1 (0.46) LMNAKMT2AMAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885KMT2A 2680/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.